MA44483A - Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires - Google Patents

Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires

Info

Publication number
MA44483A
MA44483A MA044483A MA44483A MA44483A MA 44483 A MA44483 A MA 44483A MA 044483 A MA044483 A MA 044483A MA 44483 A MA44483 A MA 44483A MA 44483 A MA44483 A MA 44483A
Authority
MA
Morocco
Prior art keywords
immune
oncological
methods
adverse events
treatments
Prior art date
Application number
MA044483A
Other languages
English (en)
Inventor
Rachael L Brake
Eric H Westin
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA44483A publication Critical patent/MA44483A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA044483A 2016-03-24 2017-03-24 Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires MA44483A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312671P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
MA44483A true MA44483A (fr) 2019-01-30

Family

ID=58489432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044483A MA44483A (fr) 2016-03-24 2017-03-24 Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires

Country Status (5)

Country Link
US (2) US11760803B2 (fr)
EP (1) EP3433275B1 (fr)
JP (3) JP7069032B2 (fr)
MA (1) MA44483A (fr)
WO (1) WO2017165778A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072657B2 (en) * 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
MA44483A (fr) * 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017218434A1 (fr) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Méthode de traitement de maladie intestinale inflammatoire
SG11202007018QA (en) * 2018-02-02 2020-08-28 Oncoimmune Inc Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
US20240288449A1 (en) * 2021-06-21 2024-08-29 Institut Gustave Roussy Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapy
EP4720125A1 (fr) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Compositions d'anticorps anti-intégrine alpha4beta7 et procédés d'utilisation
EP4762093A1 (fr) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Protéines de liaison à l'intégrine alpha 4 bêta 7 et procédés d'utilisation

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US748802A (en) 1904-01-05 Territory
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (fr) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7322582B2 (en) 2003-07-17 2008-01-29 Mind Wurx, Llc Enhanced shopping cart with lowered center of gravity and frame therefor
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
KR20070041781A (ko) 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
WO2006029219A2 (fr) 2004-09-08 2006-03-16 Ohio State University Research Foundation Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1948691A1 (fr) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L INTEGRINE a4ß7
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
EP2007808A4 (fr) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc Protéines de liaison comportant une charnière d'immunoglobulines et des régions fc ayant des fonctions effectrices altérées
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2009075813A1 (fr) 2007-12-12 2009-06-18 Sciclone Pharmaceuticals, Inc. Traitement d'un mélanome avec des peptides d'alpha-thymosine en association avec des anticorps contre l'antigène 4 associé au lymphocyte t cytotoxique (ctla4)
WO2009100140A1 (fr) 2008-02-04 2009-08-13 Medarex, Inc. Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
WO2010014784A2 (fr) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
WO2010098788A2 (fr) 2008-08-25 2010-09-02 Amplimmune, Inc. Antagonistes de pd-i et procédés de traitement d'une maladie infectieuse
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトｃｄ２７に結合する抗体およびその使用
US20130156768A1 (en) 2010-08-26 2013-06-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CA2833636A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2013019620A2 (fr) 2011-07-29 2013-02-07 Glaxosmithkline Llc Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
EP2912063A1 (fr) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
US20140323533A1 (en) 2013-04-29 2014-10-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
PT3134123T (pt) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
LT3142751T (lt) 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP3012270A1 (fr) 2014-10-23 2016-04-27 Institut Gustave Roussy Produits pour moduler la composition microbienne afin d'améliorer l'efficacité d'un traitement du cancer avec un bloqueur de vérification immunitaire
EP3224280A1 (fr) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab utilisable en vue du traitement de la maladie de crohn fistulisante
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
JP2018514562A (ja) * 2015-04-29 2018-06-07 セヴン ヒルズ インタレスツ リミテッド ライアビリティ カンパニー 小分子インテグリン受容体−リガンドアゴニストアジュバントを含む免疫治療のための新規組成物及び方法
MA44483A (fr) * 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires

Also Published As

Publication number Publication date
JP7560508B2 (ja) 2024-10-02
JP2024175093A (ja) 2024-12-17
JP2019512523A (ja) 2019-05-16
WO2017165778A1 (fr) 2017-09-28
EP3433275A1 (fr) 2019-01-30
US20190040140A1 (en) 2019-02-07
US11760803B2 (en) 2023-09-19
JP2022105157A (ja) 2022-07-12
JP7069032B2 (ja) 2022-05-17
US12590157B2 (en) 2026-03-31
US20240247067A1 (en) 2024-07-25
EP3433275B1 (fr) 2026-08-12

Similar Documents

Publication Publication Date Title
EP3496739A4 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3645739A4 (fr) Procédés et compositions pour le traitement du mélanome
EP3331571A4 (fr) Compositions et procédés pour traiter des infections virales
EP3458158A4 (fr) Compositions et procédés permettant de traiter l'eczéma
EP3474879A4 (fr) Compositions et procédés de traitement d'un mélanome
EP3541408C0 (fr) Compositions et méthodes pour le traitement de l'angiogenèse aberrante
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3204007C0 (fr) Composés de la triazolopyridine et méthodes pour le traitement de la fibrose kystique
EP3474849A4 (fr) Compositions et méthodes pour la détection et le traitement du diabète
EP3458099A4 (fr) Compositions et procédés de traitement de l'acné vulgaire
EP3448981A4 (fr) Compositions et procédés pour réaliser des séparations magnétiflottantes
EP3307296A4 (fr) Procédés et compositions pour traiter des états associés au vieillissement
EP3513795C0 (fr) Agent améliorant la fonction visuelle, et procédé d'amélioration de la fonction visuelle
MA39722A (fr) Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
EP2850195A4 (fr) Procédés et compositions de traitement de dépôts amyloïdes
EP3389657A4 (fr) Procédés de traitement de l'hyperalgésie
EP3331542A4 (fr) Compositions et procédés pour traiter des cancers associés à l'activation d'etbr
EP3402575A4 (fr) Procédés et compositions pour le traitement de cheveux endommagés
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
EP3522873A4 (fr) Compositions et méthodes pour le traitement de la xérostomie
EP3405172A4 (fr) Procédés et compositions pour le traitement du vieillissement cutané
DE102014119391B8 (de) Vorrichtung und Verfahren zum Etikettieren von einzelnen Packungen
EP3954999C0 (fr) Compositions et procédés pour détecter et traiter un cancer ovarien
EP3471826A4 (fr) Dispositifs et procédés pour enlever les poils